BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, reported financial results for the three months and fiscal year ended December 31, 2021.

The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product Officer.

Antibody drug conjugates are the novel class of drugs which deliver the chemotherapeutic drug directly to the cancer cell.

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the publication of new findings from researchers at Memorial Sloan Kettering Cancer Center (MSKCC) and the University of Miami showing six novel mutations that prevented patients with B-cell leukemia from responding to a new class of non-covalent Bruton’s tyrosine kinase (BTK) inhibitors.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, reported fourth quarter and full year 2021 financial results and corporate highlights.

Collegium Pharmaceutical, Inc. reported its financial results for the fourth quarter and full-year 2021 and provided a corporate update.

Natus Medical Incorporated announced financial results for the three months and full year ended December 31, 2021.

Travere Therapeutics, Inc. reported its fourth quarter and full year 2021 financial results and provided a corporate update.